Protagonist Therapeutics announced positive Phase 3 results for its peptide therapeutic Rusfertide for treating Polycythemia Vera.

1 report, 0 independent Updated Jun 25

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Protagonist Therapeutics (United States)

Keep exploring

Part of

Protagonist Therapeutics submitted an NDA for its icotrokinra treatment and presented rusfertide data at the ASCO meeting. All 2 developments

The entities involved

Protagonist Therapeutics (United States)
company in Milpitas, United States

Nothing else this week.

Related events

Protagonist Therapeutics and Takeda Pharmaceutical Company entered a strategic partnership regarding the Rusfertide drug candidate, while Citi initiated coverage with a Buy rating.Jun 8

Coverage

Newest first; wire copies grouped

Jun 25Unknown outlet